|
1
|
White NM and Yousef GM: MicroRNAs:
Exploring a new dimension in the pathogenesis of kidney cancer. BMC
Med. 8:652010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen C, Xue S, Zhang J, Chen W, Gong D and
Zheng J, Ma J, Xue W, Chen Y, Zhai W and Zheng J:
DNA-methylation-mediated repression of miR-766-3p promotes cell
proliferation via targeting SF2 expression in renal cell carcinoma.
Int J Cancer. 141:1867–1878. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhai W, Li S, Zhang J, Chen Y, Ma J, Kong
W, Gong D, Zheng J, Xue W and Xu Y: Sunitinib-suppressed miR-452-5p
facilitates renal cancer cell invasion and metastasis through
modulating SMAD4/SMAD7 signals. Mol Cancer. 17:1572018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yan L, Ding B, Liu H, Zhang Y, Zeng J, Hu
J, Yao W, Yu G, An R, Chen Z, et al: Inhibition of SMYD2 suppresses
tumor progression by down-regulating microRNA-125b and attenuates
multi-drug resistance in renal cell carcinoma. Theranostics.
9:8377–8391. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Palanichamy JK and Rao DS: miRNA
dysregulation in cancer: Towards a mechanistic understanding. Front
Genet. 5:542004.
|
|
9
|
Juan D, Alexe G, Antes T, Liu H,
Madabhushi A, Delisi C, Ganesan S, Bhanot G and Liou LS:
Identification of a microRNA panel for clear-cell kidney cancer.
Urology. 75:835–841. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Redova M, Poprach A, Nekvindova J, Iliev
R, Radova L, Lakomy R, Svoboda M, Vyzula R and Slaby O: Circulating
miR-378and miR-451 in serum are potential biomarkers for renal cell
carcinoma. J Transl Med. 10:552012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhen Y, Liu J, Huang Y, Wang Y, Li W and
Wu J: miR-133b inhibits cell growth, migration, and invasion by
targeting MMP9 in non-small cell lung cancer. Oncol Res.
25:1109–1116. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zeng W, Zhu JF, Liu JY, Li YL, Dong X,
Huang H and Shan L: miR-133b inhibits cell proliferation, migration
and invasion of esophageal squamous cell carcinoma by targeting
EGFR. Biomed Pharmacother. 111:476–484. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Roskoski R Jr: ERK1/2 MAP kinases:
Structure, function, and regulation. Pharmacol Res. 66:105–143.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qin W, Dong P, Ma C, Mitchelson K, Deng T,
Zhang L, Sun Y, Feng X, Ding Y, Lu X, et al: MicroRNA-133b is a key
promoter of cervical carcinoma development through the activation
of the ERK and AKT1 pathways. Oncogene. 31:4067–4075. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li S, Cui Z and Meng X: Knockdown of
PARP-1 inhibits proliferation and ERK signals, increasing drug
sensitivity in osteosarcoma U2OS cells. Oncol Res. 24:279–286.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak JK and Schmittgen TD: Analysis of
relative gene expression data using quantitative PCR and the
2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rasmussen F: Metastatic renal cell cancer.
Cancer Imaging. 13:374–380. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gardner CS, Ensor JE, Ahrar K, Huang SY,
Sabir SH, Tannir NM, Lewis VO and Tam AL: Cryoablation of bone
metastases from renal cell carcinoma for local tumor control. J
Bone Joint Surg Am. 99:1916–1926. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Romero-Laorden N, Doger B, Hernandez M,
Hernandez C, Rodriguez-Moreno JF and Garcia-Donas J: Predictive
biomarker candidates to delineate efficacy of antiangiogenic
treatment in renal cell carcinoma. Clin Transl Oncol. 18:1–8. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rupaimoole R, Calin GA, Lopez-Berestein G
and Sood AK: miRNA deregulation in cancer cells and the tumor
microenvironment. Cancer Discov. 6:235–246. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bram EE, Stark M, Raz S and Assaraf YG:
Chemotherapeutic drug-induced ABCG2 promoter demethylation as a
novel mechanism of acquired multidrug resistance. Neoplasia.
11:1359–1370. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
To KK, Poon DC, Wei Y, Wang F, Lin G and
Fu LW: Vatalanib sensitizes ABCB1 and ABCG2-overexpressing
multidrug resistant colon cancer cells to chemotherapy under
hypoxia. Biochem Pharmacol. 97:27–37. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Reustle A, Fisel P, Renner O, Büttner F,
Winter S, Rausch S, Kruck S, Nies AT, Hennenlotter J, Scharpf M, et
al: Characterization of the breast cancer resistance protein
(BCRP/ABCG2) in clear cell renal cell carcinoma. Int J Cancer.
143:3181–3193. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sun Y, Wang C, Meng Q, Liu Z, Huo X, Sun
P, Sun H, Ma X, Peng J and Liu K: Targeting P-glycoprotein and
SORCIN: Dihydromyricetin strengthens anti-proliferative efficiency
of adriamycin via MAPK/ERK and Ca2+-mediated apoptosis
pathways in MCF-7/ADR and K562/ADR. J Cell Physiol. 233:3066–3079.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Han CK, Tien YC, Jine-Yuan Hsieh D, Ho TJ,
Lai CH, Yeh YL, Hsuan Day C, Shen CY, Hsu HH, Lin JY and Huang CY:
Attenuation of the LPS-induced, ERK-mediated upregulation of
fibrosis-related factors FGF-2, uPA, MMP-2, and MMP-9 by Carthamus
tinctorius L in cardiomyoblasts. Environ Toxicol. 32:754–763. 2017.
View Article : Google Scholar : PubMed/NCBI
|
